
|Articles|July 8, 2014
- Hematologic Malignancies
- Volume 1
- Issue 1
IPI-145 and ABT-199 for Lymphoid Malignancies
Author(s)Anas Younes, MD
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.
Advertisement
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.
Learn more about inhibiting BCL-2 > >
Articles in this issue
about 12 years ago
In the Pipeline: Potential New Treatments for AMLabout 12 years ago
Epidemiology in B-Cell Malignanciesabout 12 years ago
Pathogenesis of Follicular Lymphomaabout 12 years ago
Resistance to Ibrutinibabout 12 years ago
BCL-2 Inhibitor Combo May Offer Remissions in CLLAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
5




























